Neurogenesis, Inc. (NEUN) Research

Operating primarily within the United States, Neurogenesis, Inc. specializes in the production and distribution of dietary supplements. Its product line includes: NeuBecalm'd: Designed to alleviate the impact of both acute and chronic stress factors. NeuBecalm'd Chewables: A chewable variant that lessens stress effects while simultaneously boosting concentration. NeuRecover: Provides nutritional support for restoring neurotransmitter levels that have been diminished due to extended alcohol consumption. NeuReplenish: Assists in rebuilding and revitalizing healthy brain chemistry impaired or exhausted by prolonged use of chemical stimulants. NeuRelieve: Offers similar brain chemistry support, targeting imbalances caused by the sustained intake of anti-anxiety medications, and is intended for use alongside professional guidance during the tapering phase. NeuSlim: For weight management, this supplement aims to curb cravings for simple carbohydrates, reduce overall appetite, and promote balanced nutritional habits. NeuBecalm'd/NeuRelieve Combo: A combined offering providing comprehensive nutritional aid for individuals whose brain chemistry has been compromised by the extended consumption of prescription pain medications or illicit opiates (such as heroin or methadone). This combination product is also meant to be utilized in partnership with professional oversight during withdrawal or tapering. Beyond its product line, Neurogenesis, Inc. engages in a significant research collaboration with the University of Edinburgh, focusing on advancing diverse platform strategies to facilitate gene therapies. Established in 1984, the company maintains its headquarters in League City, Texas.

Open Neurogenesis, Inc. (NEUN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.